Publications

Journal Article
Research Support, N.I.H., Extramural
Ppublish 27 citations
Electronic publication date
July 25, 2017

View on Pubmed.gov 27879264 | View on doi.org 10.1158/0008-54...

Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.

Search for publications in this journal Cancer Res - 77(3):613-622

Abstract

Small molecules and antisense oligonucleotides that inhibit the translation initiation factors eIF4A1 and eIF4E have been explored as broad-based therapeutic agents for cancer treatment, based on the frequent upregulation of these two subunits of the eIF4F cap-binding complex in many cancer cells. Here, we provide support for these therapeutic approaches with mechanistic studies of eIF4F-driven tumor progression in a preclinical model of melanoma. Silencing eIF4A1 or eIF4E decreases melanoma proliferation and invasion. There were common effects on the level of cell-cycle proteins that could explain the antiproliferative effects in vitro Using clinical specimens, we correlate the common cell-cycle targets of eIF4A1 and eIF4E with patient survival. Finally, comparative proteomic and transcriptomic analyses reveal extensive mechanistic divergence in response to eIF4A1 or eIF4E silencing. Current models indicate that eIF4A1 and eIF4E function together through the 5'UTR to increase translation of oncogenes. In contrast, our data demonstrate that the common effects of eIF4A1 and eIF4E on translation are mediated by the coding region and 3'UTR. Moreover, their divergent effects occur through the 5'UTR. Overall, our work shows that it will be important to evaluate subunit-specific inhibitors of eIF4F in different disease contexts to fully understand their anticancer actions. Cancer Res; 77(3); 613-22. ©2016 AACR.

References

Genes Dev. 2004 Apr 1;18(7):745-54

Cell. 2015 Oct 8;163(2):292-300

Mol Cell. 2014 Oct 2;56(1):79-89

Cell. 2015 Jul 2;162(1):59-71

Cited by 27 citations (total)

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Translation initiation factors and their relevance in cancer.

Electronic publication date March 6, 2019

Search for publications in this journal Curr Opin Genet Dev

Columba de la Parra [...] Robert J Schneider et al.

Deregulation of several translation initiation factors occurs in numerous types of cancers. Translation initiation factors are not merely ancillary players...

Journal Article

Cellular delivery of dinucleotides by conjugation with small molecules: targeting translation initiation for anticancer applications.

Electronic publication date August 12, 2021

Search for publications in this journal Chem Sci

Natalia Kleczewska [...] Jacek Jemielity et al.

Targeting cap-dependent translation initiation is one of the experimental approaches that could lead to the development of novel anti-cancer therapies....

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

©2016 American Association for Cancer Research.